tiprankstipranks
MAIA Biotechnology Advances with Clinical Trials and Partnerships
Company Announcements

MAIA Biotechnology Advances with Clinical Trials and Partnerships

Don't Miss our Black Friday Offers:

MAIA Biotechnology, Inc. ( (MAIA) ) has shared an announcement.

MAIA Biotechnology, Inc. is actively engaging with the financial community, presenting at the H.C. Wainwright Global Investment Conference and sharing updates on its website about their business and clinical progress, including a partnership with Regeneron. The company also announced promising survival data from a Phase 2 study of their cancer treatment, THIO, in Non-Small Cell Lung Cancer. However, investors are cautioned to consider the forward-looking nature of these statements, which are based on current management expectations and subject to risks and uncertainties that could cause actual results to differ.

See more data about MAIA stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMAIA Biotechnology Reveals Promising Phase 2 Trial Results
TheFlyMAIA Biotechnology’s THIO shows positive survival data in lung cancer study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App